National Institute for Health and Care Excellence

Chronic obstructive pulmonary disease in over 16s: diagnosis and management NICE guideline CG101 – consultation on research recommendations

Stakeholder consultation comments form

Please email your completed form to COPDupdate@nice.org.uk

The consultation period closes at 5pm on 6 August 2018

<u>Developing NICE guidelines: the manual</u> gives an overview of the processes used in reviewing NICE guidelines.

If you wish to draw our attention to published studies, please supply the full reference.

Stakeholder details	
NICE is unable to accept comments from non-registered organisations.	
If you wish your comments to be considered please register via the <u>NICE website</u> or contact the <u>registered</u> <u>stakeholder organisation</u> that most closely represents your interests and pass your comments to them.	
Stakeholder organisation	
Name of commentator	

Should this research recommendation stand?

In people with COPD, does pulmonary rehabilitation during hospital admission for exacerbation and/or in the early recovery period (within 1 month of an exacerbation) improve quality of life and reduce hospitalisations and exacerbations compared to a later (defined as after 1 month) pulmonary rehabilitation programme, and in which groups is it most clinically and cost effective?

Overall response	Comments
Yes / No	Please add comments
	Please use a separate row for each major point you wish us to address.
	Please add more rows to the table if necessary.

Should this research recommendation stand?

In people with COPD, does triple therapy improve outcomes when compared with single or double therapy?

Chronic obstructive pulmonary disease in over 16s: diagnosis and management NICE guideline CG101 – consultation on research recommendations

Overall response	Comments
Yes / No	Please add comments
	Please use a separate row for each major point you wish us to address.
	Please add more rows to the table if necessary.

Should this research recommendation stand?

In people with COPD, does mucolytic drug therapy prevent exacerbations in comparison with placebo and other therapies?

Overall response	Comments
Yes / No	Please add comments
	Please use a separate row for each major point you wish us to address.
	Please add more rows to the table if necessary.

NICE reserves the right to summarise and edit comments received during consultations, or not to publish them at all, if NICE's reasonable opinion is that the comments are voluminous, publication would be unlawful or publication would be otherwise inappropriate.